Journal Mobile Options
Table of Contents
Vol. 72, No. 2, 2003
Issue release date: March–April 2003
Psychother Psychosom 2003;72:61–70

Getting What You Ask For: On the Selectivity of Depression Rating Scales

Demyttenaere K. · De Fruyt J.
University Hospital Gasthuisberg, Department of Psychiatry, Leuven, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


A large number of rating scales has been developed to assess depression severity and change during antidepressant therapy. When reviewing the literature, the choice of the rating scales used in a particular study often seems arbitrary. The most frequently used observer rating scales, the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS), and the most frequently used self-rating scale (the Beck Depression Inventory, or BDI) were developed more than 20 years ago. Their historical background is too often forgotten and they are reflections of their origin: the HDRS and the MADRS reflect antidepressant activity while the BDI reflects psychotherapy. Moreover, the HDRS is at risk of putting ‘all depressions in one basket’, while the MADRS is at risk of putting ‘all antidepressants in one basket’. Therefore, the question whether a particular antidepressant could be more effective in a particular subtype of depression cannot be answered. Observer rating scales are more frequently used than self-rating scales, and when scales are used that do exist in an observer rating and a self-rating version, interesting differences are found. The present paper does not suggest that one scale is better than another, but suggests that a better knowledge of their differential background can help the researcher choose the correct scale for his purposes.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Snaith P: What do depression rating scales measure? Br J Psychiatry 1993;163:293–298.
  2. Möller HJ: Rating depressed patients: Observer- vs. self-assessment. Eur Psychiatry 2000;15:160–172.
  3. Carrol BJ, Fielding JM, Blashke TG: Depression rating scales: A critical review. Arch Gen Psychiatry 1973;28:361–366.
  4. Snaith RP: Rating scales. Br J Psychiatry 1981;138:512–514.
  5. Costello CG: Research on symptoms versus research on syndromes. Br J Psychiatry 1992;160:304–308.
  6. van Praag HM: Reconquest of the subjective. Against the waning of psychiatric diagnosing. Br J Psychiatry 1992;160:266–271.
  7. Healy D: The case for an individual approach to the treatment of depression. J Clin Psychiatry 2000;61(suppl 6):18–23.
  8. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  9. Hamilton M: The development of a scale for primary depressive illness. Br J Clin Psychol 1967;6:278–296.
  10. Healy D: The antidepressant era. Cambridge, Harvard University Press, 1997.
  11. Linden M, Borchelt M, Barnow S: The impact of somatic morbidity on the Hamilton Depression Rating Scale in the very old. Acta Psychiatr Scand 1995;92:150–154.
  12. Gibbons RD, Clark DC, Kupfer DJ: Exactly what does the Hamilton depression rating scale measure ? J Psychiatr Res 1993;27:259–273.
  13. Bech P: Acute therapy of depression. J Clin Psychiatry 1993;54(suppl 8):18–27.
  14. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851–855.
  15. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J: Outcome definitions and predictors in depression. Psychother Psychosom 1998;67:266–270.
  16. Snaith RP: Present use of Hamilton depression rating scale: Observations on method of assessment in research of depressive disorders. Br J Psychiatry 1996;168:594–597.
  17. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ: The responsiveness of the Hamilton depression rating scale. J Psychiatr Res 2000;34:3–10.
  18. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG: Quantitative rating of depressive states. Acta Psychiatr Scand 1975 ;51:161–170.
  19. Maier W, Philipp M: Improving the assessment of severity of depressive states: A reduction of the Hamilton depression scale. Pharmacopsychiatry 1985;18:114–115.
  20. O’Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF: Sensitivity of the six-item Hamilton depression rating scale. Acta Psychiatr Scand 1997 ;95 :379–384.
  21. Hooper CL, Bakish D: An examination of the sensitivity of the six-item Hamilton rating scale for depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 2000;25:178–184.
  22. Montgomery S, Åsberg M: A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
  23. Galinowski A, Lehert P: Structural validity of MADRS during antidepressant treatment. Int Clin Psychopharmacol 1995;10:157–161.
  24. Åsberg M, Montgomery S, Perris C, Schalling D, Sedvall G: A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978.
  25. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory of measuring depression. Arch Gen Psychiatry 1961;4:53–61.
  26. Beck AT, Steer RA: Beck Depression Inventory Manual. New York, Psychological Corporation, 1987.
  27. Beck AT, Steer RA, Brown GK: BDI-II Manual, ed 2. New York, Psychological Corporation, 1996.
  28. Brown-DeGagne AM, McGlone J, Santor DA: Somatic complaints disproportionally contribute to Beck Depression Inventory estimates of depression severity in individuals with multiple chemical sensitivity. J Occup Environ Med 1998;40:862–869.
  29. Beck AT, Guth D, Steer RA, Ball R: Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997;35:785–791.
  30. Richter P, Werner J, Bastine R, Heerlein A, Kick H, Sauer H: Measuring treatment outcome by the Beck Depression Inventory. Psychopathology 1997;30:234–240.
  31. Ahava GW, Iannone C, Grebstein L, Schirling J: Is the Beck Depression Inventory reliable over time? An evaluation of multiple test-retest reliability in a nonclinical college student sample. J Pers Assess 1998;70:222–231.
  32. Dahlstrom WG, Brooks JD, Peterson CD: The Beck Depression Inventory: Item order and the impact of response sets. J Pers Assess 1990;55:224–233.
  33. Kitamura T: Self-rating depression rates: Some methodological issues; in Maj M, Sartorius N (eds): Depressive Disorders, vol 1 in WPA Series Evidence and Experience in Psychiatry. New York, Wiley, 1999 pp 77–79.
  34. Iwata N, Roberts CR, Kawakami N: Japan-US comparison of responses to depression scale items among adult workers. Psychiatry Res 1995;58:237–245.
  35. Iwata N, Umesue M, Egashira K, Hiro H, Mizoue T, Mishima N, Nagata S: Can positive affect items be used to assess depressive disorders in the Japanese population? Psychol Med 1998;28:153–158.
  36. Carroll BJ, Feinberg M, Smouse PE, Rawson SG, Greden JF: The Carroll rating scale for depression. 1. Development, reliability and validation. Br J Psychiatry 1981;138:194–200.
  37. Svanborg P, Åsberg M: A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 1994;89:21–28.
  38. Svanborg P, Åsberg M: A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Åsberg Depression Rating Scale (MADRS). J Affect Disord 2001;64:203–216.
  39. Möller HJ, von Zerssen D: Self-rating procedures in the evaluation of antidepressants. Psychopathology 1995;28:291–306.
  40. Bent-Hansen J, Lauritzen L, Clemmensen L, Lunde M, Korner A: A definite and a semidefinite questionnaire version of the Hamilton/melancholia (HDS/MES) scale. J Affect Disord 1995;33:143–150.
  41. Mattila-Evenden M, Svanborg P, Gustavsson P, Asberg M: Determinants of self-rating and expert-rating concordance in psychiatric out-patients, using the affective subscales of the CPRS. Acta Psychiatr Scand 1996;94:386–396.
  42. Sayer NA, Sackeim HA, Moeller JR, Prudic J, Devanand DP, Coleman EA, Kierksky JE: The relations between observer-rating and self-report of depressive symptomatology. Psychol Assess 1993;5:350–360.

    External Resources

  43. Enns MW, Lersen DK, Cox BJ: Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord 2000;60:33–41.
  44. Rush JA, Hiser W, Giles DE: A comparison of self-reported versus clinician-rated symptoms of depression. J Clin Psychiatry 1987;48:246–248.
  45. Corruble E, Legrand JM, Zvenigorowski H, Duret C, Guelfi JD: Concordance between self-report and clinician’s assessment of depression. J Psychiatr Res 1999;33:457–465.
  46. Riskind JH, Beck AT, Brown G, Steer RA: Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987;175:474–479.
  47. Cooper PJ, Fairburn CG: The depressive symptoms of bulimia nervosa. Br J Psychiatry 1986;148:268–274.
  48. Hotopf M, Sharp D, Lewis G: What’s in a name? A comparison of four psychiatric assessments. Soc Psychiatry Psychiatr Epidemiol 1998;33:27–31.
  49. Beck AT, Ward CH, Mendelson M: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  50. Leon AC, Shear MK, Portera L, Klerman GL: Effect size as a measure of symptom-specific drug change in clinical trials. Psychopharmacol Bull 1993;29:163–167.
  51. Nelson CJ, Mazure CM: A scale for rating tricyclic response in major depression: The TRIM. J Clin Psychopharmacol 1990;10:252–260.
  52. Nelson CJ, Mazure C, Quinlan DM, Jatlow PI: Drug-responsive symptoms in melancholia. Arch Gen Psychiatry 1984;41:663–668.
  53. Mazure C, Nelson JC, Price LH: Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 1986;43:451–456.
  54. Healy D, McMonagle T: The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997;11(4 suppl):S25–S31.
  55. Partiot A, Jouvent R, Pierson A, Baruch P, Beuzen J-N, Ammar S, Widlöcher D: Are there differential effects of fluoxetine in retarded/blunted affect versus agitated/anxious depressives? A clinical study. European Psychiatry 1997;12:21–27.

    External Resources

  56. Gelfin Y, Gorfine M, Lerer B: Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998;155:290–292.
  57. Spielberger CD, Gorsuch RL, Lushene RD: STAI Manual. Palo Alto, Consulting Psychologists Press, 1970.
  58. Fazio AF: A concurrent validational study of the NCHS General Well-Being Schedule. Vital Health Stat 2 1977;73:1–53.

    External Resources

  59. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993;29:321–326.
  60. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, Terpstra J, Turner RA, Reus VI: Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373–379.
  61. Buss AH, Durkee A: An inventory for assessing different kinds of hositility. J Consult Psychol 1957;21:343–349.
  62. Watson D, Clark LA, Tellegen A: Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 1988;54:1063–1070.
  63. Bech P, Bolwig PK, Kramp P, Rafaelsen OJ: The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Evaluation of objectivity and inter-observer reliability. Acta Psychiatr Scand 1979;59:420–430.
  64. Fava GA, Mangelli L, Ruini C: Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001;70:171–175.
  65. Rafanelli C, Park SK, Ruini C, Ottolini F, Cazzaro M, Fava GA: Rating well-being and distress. Stress Med 2000;16:55–61.

    External Resources

  66. Thunedborg K, Black CH, Bech P: Beyond the Hamilton Depression Scores in long-term treatment of manic-melancholic patients: Prediction of recurrence of depression by quality of life measurements. Psychother Psychosom 1995;64:131–140.
  67. Hoyer J, Fecht J, Lauterbach W, Schneider R: Changes in conflict, symptoms and well-being during psychodynamic and cognitive-behavioral alcohol inpatient treatment. Psychother Psychosom 2001;70:209–215.
  68. Mangelli L, Gribbin N, Buchi S, Allard S, Sensky T: Psychological well-being in rheumatoid arthritis. Psychother Psychosom 2002;71:112–116.
  69. Oken D: Multiaxial diagnosis and psychosomatic model of disease. Psychosom Med 2000;62:171–175.
  70. Dubini A, Bosc M, Polin V: Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning. J Psychopharmacol 1997;11(4 suppl):S17–S23.
  71. Swindle R, Koenke K Braun LA: Energy and improved workplace productivity in depression; in Farquhar I (ed): Investing in Health: The Social and Economic Benefits of Health Care Innovation. Amsterdam, Elsevier, 2001, pp 323–341.
  72. Otto MW, Nierenberg AA: Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 2002;71:241–243.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50